|1.||Supuran, Claudiu T: 78 articles (09/2015 - 03/2003)|
|2.||Scozzafava, Andrea: 43 articles (09/2015 - 03/2002)|
|3.||Vullo, Daniela: 28 articles (05/2015 - 03/2003)|
|4.||Winum, Jean-Yves: 16 articles (06/2015 - 01/2004)|
|5.||Innocenti, Alessio: 14 articles (10/2009 - 11/2004)|
|6.||Montero, Jean-Louis: 12 articles (05/2011 - 01/2004)|
|7.||Cecchi, Alessandro: 8 articles (10/2009 - 11/2004)|
|8.||Carta, Fabrizio: 7 articles (09/2015 - 08/2012)|
|9.||Ceruso, Mariangela: 7 articles (06/2015 - 05/2014)|
|10.||Poulsen, Sally-Ann: 6 articles (04/2014 - 04/2007)|
10/01/1977 - "Bisnitrosoureas were effective against AH-13 and L-1210, bisnitrosoguanidines were effective against AH-13 alone, and bisnitrosotoluene-sulfonamides were ineffective against both tumor lines. "
04/24/2014 - "Our study highlights the potential of cyclic secondary sulfonamides to be exploited for the discovery of potent, cancer-selective CA inhibitors."
11/03/2015 - "CA9 inhibitor such as sulfonamides is known to block CA9 activation and reduce tumor growth consequently. "
07/23/2014 - "Toward tumor-associated hCA XII compounds 6c and 10a (KI = 2.7 and 2.8 nM, respectively) showed a better inhibitory potency than reference sulfonamides MZA and IND (KI = 3.4 nM)."
07/11/2013 - "Strong selectivity toward tumor-associated hCA IX, without inhibiting the offtarget hCA II, was observed, pointing out to a new mechanism of action compared to classical sulfonamides."
06/01/2012 - "In steers and dairy cows, the sulfonamides are effective in the treatment of respiratory disease and general infections. "
12/01/2011 - "In order to evaluate the efficacy of sulfonamides against experimental Isospora suis infections in suckling piglets (oral infection with 1,500 sporulated oocysts of I. suis per piglet on the fourth day of life), two trials were conducted. "
01/01/2014 - "Based on filamentous Gram-positive organisms identified in earlier biopsy material, infection by an Actinomyces sp. was suspected and the dog showed clinical improvement on a trial of potentiated sulfonamides. "
11/02/1968 - "[Controlled study of 3 sulfonamides in chronic urinary and bronchial infections]."
04/14/1949 - "The occurrence of infection after pulmonary resection; a study of the effectiveness of sulfonamides and antibiotic agents during a 6-year period, 1942-1947."
|3.||Urinary Tract Infections (Urinary Tract Infection)
01/01/1980 - "The results of the trial were comparable to those generally achieved with sulfonamides in the treatment of acute urinary tract infections."
01/01/1985 - "They suffered from acute urinary tract infection and were treated with conventional dosage regimen of either of the sulfonamides. "
12/01/1971 - "[Significance of sulfonamides in the treatment of urinary tract infections. "
09/01/1970 - "The use of sulfonamides in urinary tract infection."
11/28/1966 - "Long-acting sulfonamides in urinary tract infections."
|4.||Communicable Diseases (Infectious Diseases)
08/15/2014 - "These sulfonamides may be useful tools for understanding the physiological role of bacterial CAs in pathogenesis of some infectious disease."
01/01/2012 - ""A startling new chemotherapeutic agent": pediatric infectious disease and the introduction of sulfonamides at Baltimore's Sydenham Hospital."
03/07/1961 - "[The new sulfonamides in the treatment of infectious diseases of childhood]."
02/11/1961 - "[The new sulfonamides in the treatment of infectious diseases of children]."
01/01/2002 - "Antimicrobial sulfonamides were the first antimicrobial agents used effectively to treat infectious diseases. "
05/01/2014 - "However, women with bacterial cystitis are treated with short-duration potentiated sulfonamides because longer courses of beta-lactams result in lower cure and higher recurrence rates. "
02/01/2003 - "They are the first-line treatment of acute uncomplicated cystitis in patients who cannot tolerate sulfonamides or TMP, who live in geographic areas with known resistance >10% to 20% to TMP-SMX, or who have risk factors for such resistance. "
07/08/2002 - "They are the first-line treatment of acute uncomplicated cystitis in patients who cannot tolerate sulfonamides or TMP, who live in geographic areas with known resistance >10% to 20% to TMP-SMX, or who have risk factors for such resistance. "
|1.||Anti-Bacterial Agents (Antibiotics)
|2.||Thymidine Monophosphate (TMP)
|5.||Trimethoprim-Sulfamethoxazole Combination (Co-Trimoxazole)
|7.||Carbonic Anhydrases (Carbonic Anhydrase)
|8.||Streptomycin (Streptomycin Sulfate)
|10.||Anti-Infective Agents (Microbicides)
|1.||Induced Hyperthermia (Thermotherapy)
|2.||Drug Therapy (Chemotherapy)
|4.||Investigational Therapies (Experimental Therapy)